Impact of QALY-equivalence assumptions on vaccine cost effectiveness
- PDF / 186,476 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 79 Downloads / 187 Views
PharmacoEconomics & Outcomes News 867, p18 - 28 Nov 2020 Impact of QALY-equivalence assumptions on vaccine cost effectiveness Sensitivity analysis using alternative QALY-equivalent social value judgments on the value of health outcomes can impact cost-effectiveness analysis (CEA) of vaccines, according to findings of a study published in Value in Health. Varicella-zoster virus (VZV) vaccines prevent varicella zoster virus infections (chickenpox) in children and herpes zoster (shingles) in adults. Sensitivity analysis was performed on a previous CEA of a VZV vaccination programme in the UK, in which the first dose was administered at one year of age and the second dose was adminstered at 4 years of age. The first part of the analysis was based on disease outcomes only, and the second part of the analysis included adverse events (AEs; moderate pain was assumed for one day after vaccination, equivalent to a loss of 0.00045 QALYs per dose). Cost effectiveness was assessed over a 50-year time horizon in a UK healthcare setting. Approximately 600 000 cases of varicella were prevented over 50 years, 69% due to the direct protective effect of the vaccine and 31% due to herd protection. Re-evaluating QALYs for age groups (
Data Loading...
